Mamta Garg
Leicester Royal Infirmary(GB)University Hospitals of Leicester NHS Trust(GB)Sudha Hospital and Medical Research Centre(IN)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Myeloproliferative Neoplasms: Diagnosis and Treatment, Cancer Treatment and Pharmacology, Peptidase Inhibition and Analysis
Most-Cited Works
- → Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma(2017)970 cited
- → Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial(2019)434 cited
- → Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial(2021)374 cited
- → Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial(2018)337 cited
- → Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial(2020)314 cited
- → A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline